Therefore, we propose that understanding the molecular mechanisms underlying the response to DSB induction by chemotherapeutic agents, which leads to PARP-1-mediated IKKγ/NF-κB signal pathway activation, is of great significance for improving the chemotherapeutic regimens required for successfully treating leukemia patients. The gene discussed is NFKB1; the disease is leukemia.